Acrivon updates pipeline and AP3 data; cash runway into Q4 2024

Acrivon Therapeutics, Inc.

Cash and marketable securities as of Dec 31, 2022 provide runway into at least Q4 2024.
OncoSignature enriched ORR to 47% (NCI trial) and 58% (Lilly trial) vs 0% in non-responders.
ACR-368 (CHK1/2) Phase 2 with registrational intent; new sensitive indications: endometrial and bladder cancer.
WEE1 and PKMYT1 inhibitors expected to enter IND-enabling studies in 2023.
Initial ACR-368 combination clinical readouts anticipated in H2 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.